enalapril / Generic mfg. - LARVOL DELTA

Severe symptomatic cardiac dysfunction in a patient with BRAF V600E-mutated metastatic colorectal cancer treated with encorafenib, binimetinib, and cetuximab: a case report. (PubMed, J Pharm Health Care Sci) - "This case highlights two crucial insights into BRAF/MEK inhibitor-associated CD. First, even severe symptomatic CD can be effectively managed and reversed upon immediate discontinuation of binimetinib and initiation of cardiotropic medications. Second, in such a severe case, rapid recovery is observed. Once stabilized, BRAF-targeted treatment could be continued as doublet therapy without binimetinib to ensure safety and disease control. However, regular echocardiographic surveillance is essential, with an interval shorter than 4 months, based on the clinical course of this case. Additionally, early recognition of CD may be improved by closely monitoring patients' symptoms and complaints through a multidisciplinary approach."

Journal • Cardiovascular • Colorectal Cancer • Heart Failure • Oncology • Pulmonary Disease • Solid Tumor • BRAF

Functional impact of new repressors of radioiodide uptake (ATA 2025) - "Of the tested drugs, 3 significantly inhibited NIS function in TPC-1-NIS cells: Enalapril, amitriptyline and sulindac (66%, 50% and 58% suppression; p = 0.0021, 0.0005 and 0.0087, respectively)...Our preliminary work identifies and validates 3 commonly prescribed drugs which inhibit radioiodide uptake, with clear potential impact on patient outcomes."

Solid Tumor • Thyroid Gland Carcinoma

Functional impact of new repressors of radioiodide uptake (ATA 2025) - "Of the tested drugs, 3 significantly inhibited NIS function in TPC-1-NIS cells: Enalapril, amitriptyline and sulindac (66%, 50% and 58% suppression; p = 0.0021, 0.0005 and 0.0087, respectively)...Our preliminary work identifies and validates 3 commonly prescribed drugs which inhibit radioiodide uptake, with clear potential impact on patient outcomes."

Solid Tumor • Thyroid Gland Carcinoma

PARACHUTE-HF: Randomized trial comparing sacubitril/valsartan with enalapril in patients with HFrEF caused by chronic Chagas cardiomyopathy (ESC-WCC 2025) - No abstract available

Clinical • Cardiomyopathy • Cardiovascular

Longitudinal changes in atherogenic index of plasma (AIP), stroke risk in hypertensive adults, and the role of folic acid supplementation (ESC-WCC 2025) - "Conclusion This study found that an increase in AIP over time significantly elevated the risk of first stroke among hypertensive patients, even with daily enalapril treatment. More importantly, the addition of a low-dose folic acid supplement appeared to mitigate this association, reducing the impact of AIP increase on incidence stroke risk."

Clinical • Cardiovascular • Ischemic stroke

Canagliflozin Ameliorates Myocardial Fibrosis and Cardiac Function in Chronic Heart Failure: A Dose-Independent Therapeutic Approach. (PubMed, J Cell Mol Med) - "The rats were then randomised into five groups: control rats, chronic heart failure rats, rats treated with a low dose of canagliflozin, rats treated with a high dose of canagliflozin and rats treated with enalapril. In summary, canagliflozin could directly improve myocardial fibrosis to control the progression of chronic heart failure. Canagliflozin may not be dose-dependent in the treatment of chronic heart failure."

Journal • Cardiovascular • Congestive Heart Failure • Fibrosis • Heart Failure • Immunology • COL3A1 • NECTIN1

Pharmacological inhibition of apoptosis, necroptosis, and ferroptosis confers effective cardioprotection in post-myocardial infarction in rats. (PubMed, Sci Rep) - "A rat model of MI was used in this study and post-MI rats were randomly assigned into 5 subgroups (n = 7/group): (1) vehicle (3%V/V DMSO), (2) enalapril (10 mg/kg), (3) zVAD-FMK (1 mg/kg), (4) Necrostatin-1 (1.65 mg/kg), or (5) Ferrostatin-1 (2 mg/kg)...Treatment with zVAD-FMK, Necrostatin-1, and Ferrostatin-1 mitigated pathological cardiac remodeling, reduced apoptosis and necroptosis-mediated myocardial injury, alleviated mitochondrial dysfunction, and improved cardiac function in post-MI rats. These findings indicated that inhibition of apoptosis and necroptosis could be novel strategies for treatment in post-MI conditions."

Journal • Preclinical • Cardiovascular • Congestive Heart Failure • Heart Failure • Metabolic Disorders • Myocardial Infarction

Enalapril mitigates senescence and aging-related phenotypes in human cells and mice via pSmad1/5/9-driven antioxidative genes. (PubMed, Elife) - "At the organismal level, enalapril has been shown to bolster the physiological performance of various organs; it notably enhances memory capacity and renal function and relieves lipid accumulation. Our work highlights the potential of enalapril to augment antioxidative defenses and combat the effects of aging, thereby indicating its promise as a treatment strategy for aging-associated diseases and its use for healthy aging."

Journal • Preclinical • Cardiovascular • Hypertension

Clinical evaluation of a novel fixed-dose combination tablet (Sentorphil® ForteGold) versus compounded powdered medications in dogs with myxomatous mitral valve disease: a randomized, double-blind study. (PubMed, Front Vet Sci) - "In a randomized, double-blind clinical trial, 60 client-owned dogs diagnosed with ACVIM stage C MMVD were assigned to receive either a novel fixed-dose combination tablet (Sentorphil® ForteGold) or a compounded powdered mixture of torsemide, pimobendan, enalapril, and spironolactone. Its formulation ensures accurate dosing, improved owner compliance, and enhanced clinical outcomes. Further studies with larger populations and extended follow-up periods are warranted to confirm these findings."

Clinical • Journal • Cardiovascular

Primary vesicoureteral reflux presenting as hypertensive crisis and thrombotic microangiopathy. (PubMed, Hipertens Riesgo Vasc) - "After 4 years, he has progressed to stage III chronic kidney disease, and his blood pressure is well controlled on enalapril. This case highlights the importance of early diagnosis and blood pressure monitoring in patients with renal scarring to prevent severe complications like hypertensive crises and irreversible renal damage."

Journal • Chronic Kidney Disease • Infectious Disease • Nephrology • Pediatrics • Renal Disease

Novel presentation of Takayasu arteritis in a young girl: severe dystonia, stroke and left ventricular thrombus. (PubMed, BMJ Case Rep) - "Treatment included corticosteroids, low molecular weight (LMW) heparin, enalapril, aspirin and warfarin. To the best of our knowledge, dystonia as a presenting feature of cerebral ischaemia in paediatric TAK has not been previously reported. This case underscores the importance of early recognition and management of atypical neurovascular features in childhood vasculitis."

Journal • Cardiovascular • CNS Disorders • Congestive Heart Failure • Cough • Dystonia • Heart Failure • Hematological Disorders • Movement Disorders • Musculoskeletal Pain • Pain • Pediatrics • Pulmonary Disease • Respiratory Diseases • Rheumatology • Thrombosis • Vasculitis

[Translated article] Cost-utility of sacubitril/valsartan in heart failure with reduced ejection fraction in Spain. (PubMed, Farm Hosp) - "This study shows that starting sacubitril/valsartan from hospital admission for heart failure is cost-effective from the perspective of the National Health Service in Spain."

HEOR • Journal • Cardiovascular • Congestive Heart Failure • Heart Failure

Sacubitril/valsartan and Quality of Life Assessed Using the EuroQol 5-Dimension 3-Level Questionnaire Level Sum Score (EQ-5D-3L-LSS) in Patients with HFrEF and HFmrEF/HFpEF. (PubMed, Eur Heart J Cardiovasc Pharmacother) - P3 | "Sacubitril/valsartan significantly reduced the risk of HF events and improved health status across the LSS spectrum in HFrEF and HFmrEF/HFpEF."

HEOR • Journal • Cardiovascular • Congestive Heart Failure • Heart Failure

Changes in cardiac structure and function are associated with health-related quality of life in heart failure patients with reduced ejection fraction: Results from the EVALUATE-HF trial. (PubMed, Eur J Heart Fail) - P4 | "In the EVALUATE-HF trial, increases in mitral e' velocities and decreases in septal E/e' ratio and LAVi were associated with improved KCCQ-12 scores over 24 weeks, after adjusting for treatment assignment. These findings suggest that reductions in left ventricular filling pressures and left atrial size are closely coupled with improved physical function and quality of life in HFrEF patients, which may provide insights into the early benefits of sacubitril-valsartan."

HEOR • Journal • Cardiomyopathy • Cardiovascular • Congestive Heart Failure • Heart Failure

Left Adrenalectomy For Pheochromocytoma, Describing The Technique Step By Step (ACS-CLINCON 2025) - "Her medical history includes hypertension, diagnosed in April 2022, for which she takes enalapril 20 mg twice a day, and a cesarean section at 23 years old...Patient Position (Work Comfortably) Trocar Placement (Ergonomic) Release of the Splenic Flexure of the Colon and the Splenocolic Ligaments (Exposure)Identification of the Left Kidney, Tail of the Pancreas, and Spleen (Continue to Expose) Identify the Left Phrenic Artery (This Will Lead You to the Problem) Identify the Left Adrenal Gland and Dissect the Perirenal Gerota's Fascia (This is Where the Surgery Begins)Open Gerota's fascia from the diaphragm to the renal hilum, and continue opening it just below the adrenal gland. Identification and Ligation of the Adrenal Vessels (First the Artery, Then the Vein) Extraction of the Surgical Specimen Using a Bag Better do not use drainage Make complete hemostasis, review port closure with the camera and finally make a TAP Block"

Cardiovascular • Hypertension • Oncology • Solid Tumor

Evidentiary Landscape of Heart Failure Therapies, Regulatory Decisions, and Translation Into Guidelines. (PubMed, J Am Coll Cardiol) - "Of the drugs approved for HFrEF, only 2 reduced mortality (sacubitril/valsartan in the PARADIGM-HF trial and dapagliflozin in the DAPA-HF trial)...Four trials, 1 with finerenone (FINEARTS-HF trial), 2 with semaglutide (STEP-HFpEF/DM trial), and 1 with tirzepatide (SUMMIT trial) met their primary endpoint in patients with HFpEF and are currently under review for approval. In contrast, before 2015, the U.S. Food and Drug Administration approved 11 drugs (captopril, enalapril, valsartan, candesartan, long-acting metoprolol succinate, bisoprolol, carvedilol, digoxin, isosorbide dinitrate-hydralazine, spironolactone, and epleronone) for patients with chronic stable HFrEF but none for HFpEF. All 11 drugs reduced mortality and morbidity except for digoxin, which only reduced hospitalization for heart failure. This state-of-the-art review examines the evidentiary support for regulatory actions and incorporation into guidelines of heart therapies approved since 2015."

Journal • Review • Cardiovascular • Congestive Heart Failure • Heart Failure

Molecular basis of domain-specific angiotensin I-converting enzyme inhibition by the antihypertensive drugs enalaprilat, ramiprilat, trandolaprilat, quinaprilat and perindoprilat. (PubMed, FEBS J) - "None of the binding modes of the inhibitors extend beyond the S1-S2' subsites to make use of the unique nACE/cACE residues that have been shown to influence domain selectivity. These findings supplement our understanding of ACE inhibition by the clinically used ACE inhibitors, and this information should be useful in the future design of more domain-selective inhibitors for the treatment of hypertension and cardiovascular diseases."

Journal • Cardiovascular • Fibrosis • Hypertension • Immunology

Liu Wei Di Huang Decoction Alleviates Renal Fibrosis by Inhibiting Endothelial Mesenchymal Transitions via Upregulating Sirt1 Expression and Inhibiting the Wnt/β-Catenin Signaling Pathway. (PubMed, Drug Des Devel Ther) - "Rats were divided into six groups: sham operation, UUO, low-dose LWDHD (LW-L), medium-dose LWDHD (LW-M), high-dose LWDHD (LW-H), and enalapril group...Moreover, LWDHD increased the levels of the endothelial marker CD31 and decreased the expression of fibrosis-associated proteins, such as α-smooth muscle actin (α-SMA) and vimentin, thereby mitigating renal fibrosis. LWDHD has the potential to alleviate renal fibrosis, possibly through the upregulation of Sirt1, which inhibits the Wnt/β-catenin signaling pathway and thereby reduces EndMT."

Journal • Chronic Kidney Disease • Fibrosis • Immunology • Nephrology • Renal Disease • CD31 • PECAM1 • SIRT1 • TGFB1 • VIM

Nephroprotective Effects of Tanacetum balsamita Extract on Metabolic-Induced Renal Injury (MIRI) in Rats. (PubMed, Curr Issues Mol Biol) - "Both doses of the ETB ameliorated most of the investigated parameters similarly to positive controls enalapril and acarbose. ETB benefits on MIRI-induced damages could be associated with high levels of mono- and dicaffeoylquinic acids together with a series of methoxylated flavones and flavonols, which may hold significance for its antidiabetic and nephroprotective activity."

Journal • Preclinical • Diabetes • Diabetic Nephropathy • Metabolic Disorders • Nephrology • Renal Disease • Type 2 Diabetes Mellitus

Human pharmaceuticals surface water pollution across urban gradients in the Buenos Aires Metropolitan Region, Argentina. (PubMed, Environ Toxicol Chem) - "Owing to their average annual concentrations and frequencies, acetaminophen, ibuprofen, carbamazepine, atenolol, enalapril, metformin, and sildenafil were the dominant HAPIs. Shifts in HAPIs frequencies and concentrations around the overall medians were a better indicator of seasonal variations than the absolute values affected by hydrological conditions. This study enhances understanding of the relationship between urbanization and HAPIs surface water pollution in a major metropolitan area of South America, offering valuable data for future HAPIs aquatic ecological risk assessments in the region."

Journal

Safety of Drugs in Breastfeeding Women With CKD. (PubMed, Kidney Int Rep) - "Among renin-angiotensin system inhibitors, enalapril and captopril are safe for breastfeeding. Based on limited evidence, quinapril, benazepril, candesartan, and valsartan are likely acceptable for use during breastfeeding. We found no compelling human data regarding the safety of other renin-angiotensin system inhibitors or sodium-glucose cotransporter type 2 (SGLT2) inhibitors, finerenone, sparsentan, or glucagon-like peptide-1 receptor agonists (GLP1RAs) in lactation. Immunosuppressive agents, including azathioprine, cyclosporine, tacrolimus, budesonide, rituximab, and eculizumab are acceptable for use during breastfeeding. Belimumab is most likely safe; however, data are limited...No studies were found on the safety of breastfeeding while on the newer complement inhibitors, including avacopan, ravulizumab, iptacopan, and pegcetacoplan...Human lactation data on the safety of most drugs used in the treatment of CKD are limited, making evidence-based recommendations..."

Journal • Chronic Kidney Disease • Nephrology • Renal Disease

Primary Aldosteronism in a Patient with 20 Years of Uncontrolled Hypertension: A Case of Non-Lateralizing Adrenal Adenoma (ENDO 2025) - "She remained normotensive for nearly 18 years but later developed uncontrolled hypertension despite maximized doses of enalapril, hydrochlorothiazide, amlodipine, and carvedilol...She was started on spironolactone, achieving blood pressure control with spironolactone 400 mg daily and nifedipine 60 mg daily...In non-lateralizing PA, mineralocorticoid receptor antagonists remain the cornerstone of treatment. Through this report, we emphasize the importance for timely involvement of multidisciplinary care to optimize outcomes and mitigate long-term complications associated with PA."

Clinical • Cardiovascular • Chronic Kidney Disease • Endocrine Cancer • Endocrine Disorders • Hypertension • Nephrology • Obstructive Sleep Apnea • Oncology • Renal Disease • Respiratory Diseases • Sleep Disorder • Solid Tumor

Incidental Papillary Thyroid Cancer in Primary Hyperparathyroidism: A Case Series (ENDO 2025) - "Peri-operatively he had hypertension and was managed with Doxazosin and Enalaprilat. It is unclear if factors such as calcium level or the presence of a malignant parathyroid nodule is associated with incidental PTC in patients with PH."

Clinical • Back Pain • Cardiovascular • Endocrine Cancer • Endocrine Disorders • Fatigue • Genetic Disorders • Hypertension • Metabolic Disorders • Musculoskeletal Pain • Oncology • Pain • Solid Tumor • Thyroid Gland Carcinoma • Thyroid Gland Papillary Carcinoma

ECHOCARDIOGRAPHIC EVALUATION OF CAPTIVE BORNEAN (PONGO PYGMAEUS), SUMATRAN (PONGO ABELII) AND HYBRID ORANGUTANS (PONGO SPECIES). (PubMed, J Zoo Wildl Med) - "Subjects were anesthetized with either tiletamine/zolazepam intramuscularly or a combination of tiletamine/zolazepam and medetomidine intramuscularly followed by ketamine intravenously. All patients were intubated and maintained on isoflurane gas anesthesia...One adult male Sumatran orangutan was diagnosed with mild left ventricle dysfunction and treated with enalapril 0.1 mg/kg PO SID...Regular cardiac assessment in orangutans allows early detection of heart disease and enables proactive prevention of heart failure. The study also provided preliminary data establishing heart parameters for the two orangutan species and their hybrids."

Journal • Anesthesia • Cardiovascular • Congestive Heart Failure • Heart Failure

Evaluation of the antihypertensive activity of the aqueous extract and the major flavonoid from Boldoa purpurascens Cav. leaves. (PubMed, Fitoterapia) - "Sprague Dawley rats (n = 34) were divided into six groups: normotensive control, hypertensive untreated, hypertensive + enalapril (15 mg/kg/day), hypertensive + B. purpurascens extract (40 or 80 mg/kg/day), and hypertensive + flavonoid (3 mg/kg/day)...The major flavonoid attenuated organ damage, suggesting therapeutic potential. Future studies should assess the presence of other bioactive compounds in the B. purpurascens extract, as well as clarify the mechanism of action."

Journal • Cardiovascular • CNS Disorders • Hypertension